ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 270 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $6,000 | -72.7% | 125 | -75.0% | 0.00% | -71.4% |
| Q1 2020 | $22,000 | 0.0% | 500 | 0.0% | 0.01% | +16.7% |
| Q4 2019 | $22,000 | -100.0% | 500 | -76.2% | 0.01% | -60.0% |
| Q1 2018 | $47,188,000 | -43.0% | 2,100 | -23.6% | 0.02% | -44.4% |
| Q4 2017 | $82,804,000 | -42.2% | 2,750 | -27.6% | 0.03% | -42.6% |
| Q3 2017 | $143,146,000 | +0.6% | 3,800 | -25.5% | 0.05% | +20.5% |
| Q2 2017 | $142,239,000 | -18.9% | 5,100 | 0.0% | 0.04% | -29.1% |
| Q1 2017 | $175,338,000 | +73.7% | 5,100 | +45.7% | 0.06% | +77.4% |
| Q4 2016 | $100,940,000 | -33.9% | 3,500 | -9.7% | 0.03% | +40.9% |
| Q3 2016 | $152,688,000 | +6.9% | 3,874 | -12.0% | 0.02% | -48.8% |
| Q2 2016 | $142,824,000 | +155.4% | 4,400 | +120.0% | 0.04% | +152.9% |
| Q1 2016 | $55,920,000 | +56.9% | 2,000 | +100.0% | 0.02% | +70.0% |
| Q4 2015 | $35,650,000 | +7.8% | 1,000 | 0.0% | 0.01% | 0.0% |
| Q3 2015 | $33,070,000 | – | 1,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |